Patiromer: Additional Phase IIb data

Relypsa reported additional data from the open-label, international Phase IIb AMETHYST-DN trial in 306 patients with hyperkalemia due to Type II diabetes and CKD who

Read the full 251 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE